论文部分内容阅读
在亚特兰大召开的2006年美国临床肿瘤学会年度会议上公布的一项新的针对晚期乳腺癌的随机Ⅲ期研究的结果表明,希罗达(Xeloda,卡培他滨——capecitabine)和紫杉醇(paclitaxel)联合疗法的疗效相当于已被公认的效用较高的表阿霉素(epirubicin,一种蒽环类药物)和紫杉醇联合疗法的疗效,且前者的安全性高于后者。众所周知,蒽环类药物(表阿霉素和其它)与可危机生命的蓄积心脏毒性关联;随着心脏的逐步衰竭,患者在一生中可接受治疗的次数被限制。更重要的是,鉴于希罗达和紫杉醇(又称“XP”)的配合使用不会产生蓄积副作用,因而在治疗时能够使患者更加安全。
A new randomized phase III study of advanced breast cancer published at the annual meeting of the American Society of Clinical Oncology in Atlanta in 2006 showed that Xeloda (capecitabine) and paclitaxel (paclitaxel) The efficacy of combination therapy is equivalent to the efficacy of epirubicin (epirubicin) and paclitaxel combination therapy, which has been recognized as having higher efficacy, and the safety of the former is higher than that of the latter. It is well-known that anthracyclines (epideradenic and others) are associated with life-threatening cumulative cardiac toxicity; with the gradual failure of the heart, the number of acceptable treatments for a patient in a lifetime is limited. More importantly, given that the combined use of Xeloda and paclitaxel (also known as “XP”) does not produce cumulative side effects, it can make the patient safer during treatment.